Cara Q4 2019 Earnings Report
Key Takeaways
Cara Therapeutics reported a net loss of $28.6 million for the fourth quarter of 2019, compared to a net loss of $20.7 million for the same period in 2018. The company's cash, cash equivalents, and marketable securities totaled $218.2 million at the end of 2019.
Reported positive results from the first pivotal Phase 3 efficacy trial (KALMâ„¢ -1) of KORSUVA Injection.
Reported positive results from Phase 2 trial of Oral KORSUVA in pre-dialysis patients.
Expanded clinical pruritus program for Oral KORSUVA with the initiation of Phase 2 trials in both atopic dermatitis and liver disease patients.
Expects top-line data for its pivotal KALM-2 Phase 3 global trial of KORSUVA Injection in the second quarter of 2020.
Cara
Cara
Forward Guidance
Cara Therapeutics expects its existing cash and cash equivalents and available-for-sale marketable securities as of December 31, 2019 will be sufficient to fund its currently anticipated operating expenses and capital expenditures into the second half of 2021.